S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
Why I Sued the Gov’t – And What I Recommend Now (Ad)
3 Safe Earnings Plays for a Risk-Off Market
Micron to bring microchip plant to upstate New York
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower
Stocks rise in extended rally, clawing back more ground
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Live Updates: Russia-Ukraine War
Fourth quarter opens with a bang, US futures jump sharply
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
Why I Sued the Gov’t – And What I Recommend Now (Ad)
3 Safe Earnings Plays for a Risk-Off Market
Micron to bring microchip plant to upstate New York
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower
Stocks rise in extended rally, clawing back more ground
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Live Updates: Russia-Ukraine War
Fourth quarter opens with a bang, US futures jump sharply
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
Why I Sued the Gov’t – And What I Recommend Now (Ad)
3 Safe Earnings Plays for a Risk-Off Market
Micron to bring microchip plant to upstate New York
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower
Stocks rise in extended rally, clawing back more ground
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Live Updates: Russia-Ukraine War
Fourth quarter opens with a bang, US futures jump sharply
S&P 500   3,790.93
DOW   30,316.32
QQQ   282.13
6 Benefits of Working With a Franchise Consultant or Broker
Why I Sued the Gov’t – And What I Recommend Now (Ad)
3 Safe Earnings Plays for a Risk-Off Market
Micron to bring microchip plant to upstate New York
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Tyson Foods Takes a Lickin’ and Keeps on Tickin’ Lower
Stocks rise in extended rally, clawing back more ground
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Live Updates: Russia-Ukraine War
Fourth quarter opens with a bang, US futures jump sharply
NASDAQ:TYME

Tyme Technologies - TYME Stock Forecast, Price & News

$0.31
+0.02 (+7.83%)
(As of 09/16/2022)
Add
Compare
Today's Range
$0.29
$0.33
50-Day Range
$0.24
$0.35
52-Week Range
$0.22
$1.14
Volume
67,913 shs
Average Volume
1.01 million shs
Market Capitalization
$53.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TYME stock logo

About Tyme Technologies (NASDAQ:TYME) Stock

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

Receive TYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter.

TYME Stock News Headlines

Syros Pharma to Merge with Tyme Technologies
Tyme Technologies Shares Soar on Syros Merger
A Short History of the American Lawn
See More Headlines
Receive TYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter.

TYME Company Calendar

Last Earnings
8/09/2022
Today
10/05/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TYME
Fax
N/A
Employees
17
Year Founded
N/A

Profitability

Net Income
$-23,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.47 per share

Miscellaneous

Free Float
143,104,000
Market Cap
$53.38 million
Optionable
Optionable
Beta
0.93

Key Executives

  • Mr. Richard Cunningham (Age 51)
    CEO & Director
    Comp: $789.9k
  • Mr. Steven E. Hoffman (Age 59)
    Co-Founder & Director
    Comp: $2.6M
  • Mr. Frank L. Porfido (Age 58)
    Chief Financial Officer
    Comp: $488.2k
  • Mr. James Biehl J.D.Mr. James Biehl J.D. (Age 58)
    Chief Legal Officer & Sec.
    Comp: $635.89k
  • Dr. Jonathan M. Eckard (Age 48)
    Chief Bus. Officer
  • Dr. Jan Marie-Albert Van Tornout M.D. (Age 66)
    M.Sc., Acting Chief Medical Officer













TYME Stock - Frequently Asked Questions

How have TYME shares performed in 2022?

Tyme Technologies' stock was trading at $0.6031 at the beginning of the year. Since then, TYME stock has decreased by 48.6% and is now trading at $0.31.
View the best growth stocks for 2022 here
.

When is Tyme Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our TYME earnings forecast
.

How were Tyme Technologies' earnings last quarter?

Tyme Technologies, Inc. (NASDAQ:TYME) announced its earnings results on Tuesday, August, 9th. The company reported ($0.04) earnings per share for the quarter.

What other stocks do shareholders of Tyme Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX).

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

How do I buy shares of Tyme Technologies?

Shares of TYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $0.31.

How much money does Tyme Technologies make?

Tyme Technologies (NASDAQ:TYME) has a market capitalization of $53.38 million. The company earns $-23,630,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The official website for the company is www.tymeinc.com. The company can be reached via phone at (212) 461-2315 or via email at investorrelations@tymeinc.com.

This page (NASDAQ:TYME) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.